Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JV-394 in Relapsed or Refractory CD94+ T/NK Cell Neoplasms
NCT07382817Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JV-394 in T-cell and natural killer cell neoplasms, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year and Maximum Tolerated Dose or Recommended Phase 2 Dose at 1 year. Started Feb 2026; status: recruiting.
02
Drugs
JV-394
03
Conditions
T-cell and natural killer cell neoplasms
Beyond the preview
Go deeper on NCT07382817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382817.